Core Delivery
High-Risk Drug Monitoring — compliance you can prove.
What we deliver
The work, end-to-end.
High-risk drugs are the medicines most likely to harm a patient and the area most heavily scrutinised by CQC. Most PCNs we onboard have 20–40% monitoring gaps on day one.
- Patient register validation across all high-risk drug groups
- Monitoring recall and chase processes
- Bloods review with prescribing action
- MHRA alert action and patient communication
- Documented audit trail for CQC inspection
- Monthly compliance dashboard per drug group
Outcomes
Measurable outcomes — every month.
Tracked in the BCS Impact Dashboard. Reported to your PCN every month. QA signed-off.
- Monitoring compliance % per drug group
- Patients overdue brought back into range
- Safety incidents avoided
- CQC-ready audit evidence
DES 26/27 alignment
How this maps to the Network Contract DES.
Supports the medicines safety responsibilities defined in the Network Contract DES 26/27 and demonstrates compliance with NICE guidance on high-risk medicines monitoring.
FAQs
Common questions from PCN Clinical Directors.
Which drug groups do you cover?+
All high-risk groups defined in NICE and local ICB formularies: DOACs, methotrexate, lithium, amiodarone, opioids on long-term scripts, DMARDs, and anything your ICB flags locally.
Do you write to patients?+
Yes — patient communication is included. Letters and SMS are templated in the BCS intranet and customised per practice.
How quickly can you start?+
Typically 4–6 weeks from contract signature to first monitoring cycle.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.